

NON-OPIOID
EXPAREL®
(bupivacaine liposome injectable suspension)

DENTAL AND ORAL SURGERY RESOURCES FOR EXPAREL



MORE THAN **8 MILLION ADULT PATIENTS** HAVE RECEIVED EXPAREL SINCE 2012²


**CLICK ON IMAGES BELOW
TO LEARN MORE ▼**

EXPAREL in Pediatrics


Learn more about the safety and dosing of EXPAREL in patients 6 to 17 years old.



Administrative Case Reports and Videos



Third Molar Extraction




Full maxillary
reconstruction
infiltration

Bilateral
temporomandibular
joint arthroplasty*

Patient and Care Team Resources

Additional tools such as patient wristbands, syringe stickers, and patient education materials.



Patient Wristband



OMFS Syringe Stickers

OMFS=oral maxillofacial surgery.


*A case report is also available through the link.

†Content for informational purposes only. Pacira cannot guarantee successful reimbursement for EXPAREL from the use of provided resources. Reimbursement criteria will vary by payer.

Surgeon Selector

A searchable database that allows patients to find health care providers, like you.

Register for Surgeon Selector to set your facility apart.





Reimbursement

Reimbursement codes for EXPAREL and related billing guidance are provided to ensure you have timely information.[†] To contact Pacira's dedicated reimbursement specialists:


 Email reimbursement@pacira.com

 Call the reimbursement helpline at **855-793-9727**



Ordering EXPAREL

Contact your wholesaler or order directly from Pacira.



[Continue to View Tools for Your Practice](#)

Please see Important Safety Information on next page. [CLICK HERE](#) for full Prescribing Information.

Tools for Your Practice

A tool kit is available to help you spread awareness and educate patients and the community about your non-opioid approach for managing postsurgical pain.

Differentiate your practice
by highlighting your
opioid-minimizing efforts

**Communicate with your
patients** about your approach to
postsurgical pain management and
reducing the need for opioids

**Explain the role
EXPAREL plays** in
accomplishing
these goals



Indication

EXPAREL® (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in patients aged 6 years and older to produce postsurgical local analgesia and in adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritis, and tachycardia.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for interscalene brachial plexus nerve block, and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks **other than interscalene brachial plexus nerve block**, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Full Prescribing Information is also available at www.EXPAREL.com.

References: 1. Pacira BioSciences. Pacira announces FDA approval of supplemental new drug application for EXPAREL® (bupivacaine liposome injectable suspension) in pediatric patients [press release]. Pacira website. <https://investor.pacira.com/news-releases/news-release-details/pacira-announces-fda-approval-supplemental-new-drug-0>. Published March 22, 2021. Accessed May 12, 2021. 2. Data on file. 6450. Parsippany, NJ: Pacira BioSciences, Inc.; January 2021.